Curated Wealth Partners LLC lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 83.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,464 shares of the medical instruments supplier’s stock after selling 12,400 shares during the period. Curated Wealth Partners LLC’s holdings in Insulet were worth $321,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. BlackRock Inc. acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $1,018,582,000. Arrowstreet Capital Limited Partnership boosted its position in Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the period. Man Group plc acquired a new position in Insulet during the 2nd quarter valued at approximately $78,746,000. Bank of America Corp DE acquired a new position in Insulet during the 2nd quarter valued at approximately $64,921,000. Finally, Bank of New York Mellon Corp bought a new position in Insulet during the 2nd quarter worth $60,615,000.
Analysts Set New Price Targets Several brokerages have weighed in on PODD. Benchmark dropped their target price on Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Citigroup raised their target price on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Robert W. Baird set a $175.00 price target on shares of Insulet in a report on Thursday, August 6th. Canaccord Genuity Group lowered their price target on shares of Insulet from $249.00 to $179.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Finally, BTIG Research lowered shares of Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Thirteen analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $186.68.
Check Out Our Latest Research Report on PODD Insulet Stock Performance Shares of PODD stock opened at $141.10 on Friday. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The firm has a market capitalization of $9.79 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 1.11 and a beta of 1.11. The business has a 50 day simple moving average of $140.56 and a 200 day simple moving average of $156.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.
Insulet (NASDAQ:PODD – Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm’s revenue was up 23.5% compared to the same quarter last year. During the same period last year, the firm earned $1.17 EPS. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, equities research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.
About Insulet (Free Report)
Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.
Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.
Featured Stories Five stocks we like better than Insulet Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
Zacks Premium includes access to the Zacks Style Scores as well.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.
Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.82% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Insulet (PODD - Free Report) Acton, MA-based Insulet Corporation manufactures and sells its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The company designed Omnipod, a small, lightweight, self-adhesive disposable tubeless device that can be worn in multiple locations, including the abdomen, hip, back of the upper arm, upper thigh or lower back.
PODD is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. PODD has a Growth Style Score of B, forecasting year-over-year earnings growth of 31% for the current fiscal year.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.00 to $6.51 per share. PODD boasts an average earnings surprise of +13.6%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, PODD should be on investors' short list.
Web-based data platform turns Omnipod 5 data into clear, personalized insights for users, caregivers, and healthcare professionals
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover turns critical diabetes data into clear visualizations and personalized insights, giving people with diabetes and their HCPs a shared understanding of therapy patterns to make more informed diabetes management decisions.
"The future of diabetes care is not just about generating more data, it's about making that data meaningful,” said Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Chief Medical Officer at Insulet. “Omnipod Discover simplifies data review for Omnipod 5 users and their healthcare providers so they spend less time gathering information and more time collaborating on diabetes management."
With Omnipod Discover, Omnipod 5 users get simple, personalized glucose and insulin delivery reports sent directly to their smartphone weekly, so they know where to focus their diabetes management efforts. Omnipod Discover also helps HCPs make confident clinical recommendations from a concise report by overlaying a licensed Ambulatory Glucose Profile (AGP) with key adjustable pump settings and bolus events.
Omnipod Discover has already been adopted in the United States by more than 15,000 Omnipod 5 users and over 1,800 healthcare professionals as part of Insulet's limited market release program in the U. S. It is also available to users and HCPs in Spain, Australia, Saudi Arabia, Qatar, Kuwait, UAE, and Israel.
"In today's AID (automated insulin delivery) era, clinicians need actionable insights, not more data. Omnipod Discover brings key diabetes metrics and insights together in a streamlined, easy-to-use workflow that supports clinical decision-making and patient conversations,” said Dr. Martin Sarkar, DO, ECNU, Endocrinologist at EndoCARE Diabetes & Wellness Center in Frederick, Maryland. “It also gives people with diabetes greater visibility into their therapy, helping foster engagement and trust. Omnipod Discover is an important step toward a more connected diabetes ecosystem that supports both providers and patients."
In June, Insulet presented Real-World Glycemic Outcomes1 using the Omnipod Discover platform at the American Diabetes Association’s Scientific Sessions in New Orleans, Louisiana. Use of Omnipod Discover was associated with improvements in time in range (TIR), with 32% of users seeing a clinically meaningful increase in TIR of 3% or more. These findings support the vital role that user engagement with Omnipod Discover can play in diabetes self-management.
The platform is now available to all Omnipod 5 users nationwide, with healthcare professionals able to enroll through onboarding and training provided by their dedicated Omnipod sales representative.
To enroll in Omnipod Discover, Omnipod 5 users can log into PodderCentral and follow the on-screen prompts. Healthcare professionals can visit our website to learn more or contact their dedicated Omnipod sales representative.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the third quarter of 2026 on Wednesday, November 4, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (833) 461-5787 for domestic callers, or (585) 542-9983 for international callers; the passcode is 186 295 579.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: Insulet.com or omnipod.com.
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.
Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.
It also includes access to the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.
The Style Scores are broken down into four categories:
Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.
Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.
Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Insulet (PODD - Free Report) Acton, MA-based Insulet Corporation manufactures and sells its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The company designed Omnipod, a small, lightweight, self-adhesive disposable tubeless device that can be worn in multiple locations, including the abdomen, hip, back of the upper arm, upper thigh or lower back.
PODD is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. PODD has a Growth Style Score of B, forecasting year-over-year earnings growth of 31% for the current fiscal year.
Seven analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.06 to $6.51 per share. PODD also boasts an average earnings surprise of +13.6%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, PODD should be on investors' short list.
Insulet (NASDAQ:PODD) Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.
Speaking at a Bernstein event hosted by U.S. MedTech Analyst Lee Hambright, Benjamin said Insulet now serves 26 countries, including 20 markets with Omnipod 5, and has developed manufacturing capacity intended to support growth. He said the company is on track to add more customers this year than the company had in total when he joined more than a decade ago.
Benjamin cited an estimated 1.8 million people in the U.S. living with Type 1 diabetes, with less than half using AID technology. He also pointed to approximately 2.5 million U.S. patients with insulin-intensive, or basal-bolus, Type 2 diabetes, of whom about 5% use AID technology. Globally, Insulet estimates that only about 25% of the nearly 4 million Type 1 diabetes patients in its served markets use AID. Type 2 Retention Actions Benjamin said Type 2 customers accounted for roughly 40% of Insulet’s new customer starts during the second quarter. While the company remains enthusiastic about the market opportunity, it identified higher-than-desired attrition during the first 90 days after initiation.
Insulet is pursuing four actions intended to improve conversion from an initial Omnipod start to a longer-term customer relationship:
Improving sampling workflows, including confirming prescriptions, prior authorizations, coverage discussions and customer support arrangements. Adjusting field incentives to emphasize durable customer starts and early customer success. Scaling customer service and clinical retention teams to provide additional education and support during the first 90 days. Accelerating the broader rollout of Omnipod Discover, its digital health platform. Benjamin said Insulet’s analysis indicates that retention remains strong after the first 90 days for both Type 1 and Type 2 customers. The company’s near-term focus is therefore on improving the transition from initial use to that 90-day milestone. Insulet plans to provide an update on the effort during its fourth-quarter call in February.
On the longer-term Type 2 market, Benjamin reiterated the company’s previous goal of increasing AID penetration among insulin-intensive Type 2 patients to 10% to 15% by 2028, from about 5% currently. He said the company sees potential for penetration beyond that range over time, noting that continuous glucose monitor penetration in the Type 2 insulin-intensive market is about 55%.
Digital Platform and Product Pipeline Benjamin described Omnipod Discover as a two-part platform for clinicians and people with diabetes. The clinician-facing component is designed to provide information that can support more efficient patient visits. The patient-facing component sends weekly text-message links with personalized insights, educational information and suggestions based on a user’s recent experience.
More than 10,000 people in the U.S. are enrolled in the limited release, Benjamin said. He added that Insulet has observed improvements in clinical outcomes and retention among participants, although he did not provide detailed data. The company expects to complete the full market release between now and year-end, with new customers enrolled in the platform.
Benjamin also outlined Insulet’s development roadmap. He said the company’s second-generation Omnipod 5 algorithm, which offers a lower glucose target, and its FreeStyle Libre 3 Plus integration were launched earlier this year. Omnipod 6 is expected in 2027, following clearance of its algorithm and a planned submission for the complete system.
According to Benjamin, Omnipod 6 will include an updated AID algorithm designed to deliver more automated insulin with less bolus burden, expanded wear-location flexibility and a single, updatable pod design. The updatable pod is intended to simplify prescribing and enable software updates without requiring new hardware to be manufactured and distributed.
Insulet’s Type 2 fully closed-loop system is currently in a pivotal study, with enrollment progressing, Benjamin said. The company expects the system in 2028 and described it as designed to require no insulin-setting inputs from physicians and to allow patients to self-start in a manner similar to a continuous glucose monitor. Insulet expects the simpler model could help expand adoption among primary-care providers.
International Growth, Quality and Competition International revenue grew more than 30% year over year through the second quarter, Benjamin said. He said approximately 75% of the company’s international DASH installed base has converted to Omnipod 5. As a result, Insulet expects less pricing and product-mix benefit from conversions in 2027, with volume growth expected to account for a greater portion of international expansion.
The company entered Spain with Omnipod 5 in July and expects that market to contribute to growth. It also plans to launch FreeStyle Libre 3 integration in Germany and Canada by year-end.
Benjamin said Insulet has addressed handling issues in its factories that could damage sensitive cannula components. The company reviewed manufacturing processes more broadly and implemented corrective actions, he said. Despite the disruption, Insulet did not miss a customer shipment, according to Benjamin.
Addressing prospective patch-pump competition, Benjamin said additional entrants could help expand the overall AID and patch-pump categories. He maintained that Insulet’s fully disposable, waterproof system, manufacturing scale, commercial organization and product pipeline position the company to sustain market leadership. He also said the pricing environment in the pharmacy channel remains stable, describing Insulet’s pricing as flat to slightly higher, with 2027 negotiations proceeding in line with expectations.
About Insulet (NASDAQ:PODD) Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.
The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.
Insulet NASDAQ: PODD Chief Operating Officer Eric Benjamin said the company remains focused on expanding adoption of automated insulin delivery, or AID, systems across large and underpenetrated diabetes markets, while addressing elevated early attrition among certain Type 2 diabetes customers.
Insulet Corporation (PODD) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 24, 2026 12:30 PM EDT
Company Participants
Eric Benjamin - Executive VP & COO
Conference Call Participants
Lee Hambright - Bernstein Institutional Services LLC, Research Division
Presentation
Lee Hambright
Bernstein Institutional Services LLC, Research Division
All right. Thanks, everybody, for joining. I'm Lee Hambright, U.S. med tech analyst at Bernstein. We are very happy to host Insulet. We've got COO Eric Benjamin. Thank you so much for being here, first of all.
Eric Benjamin
Executive VP & COO
Absolutely. Our pleasure.
Question-and-Answer Session
Lee Hambright
Bernstein Institutional Services LLC, Research Division
So just a reminder, if there's any questions in the room, please submit them through the app. We'll try to work them in, if possible. Maybe, Eric, starting big picture. You've been with Insulet for over a decade. Company's revenue this year will be 10x what it was in the year that you joined. Maybe talk a little bit about how Insulet has evolved over that time? And what feels most different today about the company.
Eric Benjamin
Executive VP & COO
Yes. It's been an incredible 10-year journey, Lee. But I think what's most incredible are the things that haven't changed, which are also the things that make the next decade, Insulet's best. Insulet was founded by a father who looked at injections and tubed insulin pumps and said there had to be a better way. And that drive to find a better way is what fuels all of us at Insulet and me every day, and we show up in order to find innovative ways to deliver better technology to go to market like pioneering into the pharmacy channel.
And that spirit just flows through who we are. So that hasn't changed and
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time).
The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com.
California State Teachers Retirement System grew its holdings in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 13,901.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,562,256 shares of the medical instruments supplier’s stock after acquiring an additional 14,458,254 shares during the quarter. California State Teachers Retirement System owned 21.00% of Insulet worth $2,217,103,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in PODD. BlackRock Inc. bought a new position in Insulet in the 2nd quarter valued at approximately $1,018,582,000. Norges Bank bought a new position in shares of Insulet in the 4th quarter valued at $300,794,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after acquiring an additional 1,011,369 shares in the last quarter. Man Group plc bought a new stake in Insulet during the 2nd quarter worth $78,746,000. Finally, Bank of America Corp DE bought a new stake in Insulet during the 2nd quarter worth $64,921,000.
Insulet Stock Down 2.0% Shares of NASDAQ:PODD opened at $131.96 on Friday. The business’s 50 day simple moving average is $152.36 and its two-hundred day simple moving average is $173.92. The firm has a market cap of $9.15 billion, a P/E ratio of 24.67, a PEG ratio of 1.06 and a beta of 1.08. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88.
Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same quarter in the previous year, the company posted $1.17 earnings per share. The company’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, research analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year. Wall Street Analyst Weigh In PODD has been the topic of a number of recent research reports. BTIG Research lowered Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Leerink Partners lowered shares of Insulet from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $247.00 to $145.00 in a report on Thursday, August 6th. Royal Bank Of Canada cut their target price on shares of Insulet from $245.00 to $160.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Robert W. Baird set a $175.00 price objective on Insulet in a report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 target price for the company. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $195.40.
Get Our Latest Report on Insulet
Insulet Company Profile (Free Report)
Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.
The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.
Further Reading Five stocks we like better than Insulet Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model Kroger’s Textbook Entry for Buy-and-Hold Investors AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window Amgen Drops 10% on a Trial It Didn’t Even Run Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
Amundi increased its holdings in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 13.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 507,847 shares of the medical instruments supplier’s stock after acquiring an additional 60,929 shares during the quarter. Amundi owned approximately 0.73% of Insulet worth $77,320,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. California State Teachers Retirement System grew its holdings in Insulet by 13,901.9% in the 2nd quarter. California State Teachers Retirement System now owns 14,562,256 shares of the medical instruments supplier’s stock worth $2,217,103,000 after buying an additional 14,458,254 shares in the last quarter. BlackRock Inc. bought a new position in shares of Insulet in the second quarter worth $1,018,582,000. Norges Bank acquired a new position in shares of Insulet during the fourth quarter valued at $300,794,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Finally, Man Group plc bought a new stake in shares of Insulet during the second quarter valued at about $78,746,000.
Analyst Upgrades and Downgrades Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $152.00 price objective (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Robert W. Baird set a $175.00 target price on shares of Insulet in a research note on Thursday, August 6th. Bank of America dropped their price target on shares of Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Wells Fargo & Company cut shares of Insulet from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $255.00 to $144.00 in a report on Wednesday, August 5th. Finally, Sanford C. Bernstein lowered their price objective on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $195.40.
Read Our Latest Analysis on Insulet Insulet Trading Down 3.1% Shares of NASDAQ:PODD opened at $137.92 on Thursday. The stock has a market capitalization of $9.56 billion, a price-to-earnings ratio of 25.78, a PEG ratio of 1.12 and a beta of 1.08. Insulet Corporation has a 1-year low of $126.40 and a 1-year high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The company has a 50 day moving average price of $153.61 and a 200 day moving average price of $174.97.
Insulet (NASDAQ:PODD – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. The company had revenue of $801.70 million for the quarter, compared to analysts’ expectations of $787.39 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm’s revenue was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts anticipate that Insulet Corporation will post 6.51 EPS for the current fiscal year.
Insulet Profile (Free Report)
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Further Reading Five stocks we like better than Insulet Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer Sovereign AI: Palantir and Nebius Cut the Cloud Cord Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.
Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Insulet (PODD - Free Report) Acton, MA-based Insulet Corporation manufactures and sells its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The company designed Omnipod, a small, lightweight, self-adhesive disposable tubeless device that can be worn in multiple locations, including the abdomen, hip, back of the upper arm, upper thigh or lower back.
PODD is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
Additionally, the company could be a top pick for growth investors. PODD has a Growth Style Score of B, forecasting year-over-year earnings growth of 31% for the current fiscal year.
Seven analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.05 to $6.51 per share. PODD also boasts an average earnings surprise of +13.6%.
With a solid Zacks Rank and top-tier Growth and VGM Style Scores, PODD should be on investors' short list.
Key Takeaways Insulet's Q2 Omnipod revenues rose 23.8% at constant currency as global customer adoption expanded. Insulet raised 2026 international Omnipod constant-currency growth guidance to 30-32%. Competition, tariffs, supply constraints and manufacturing expansion could pressure margins. Insulet (PODD - Free Report) is well poised for growth in the upcoming quarters, owing to its strong momentum for the Omnipod 5 automated insulin delivery (“AID”) system for both Type 1 and Type 2 populations. The company is strongly executing against its long-term priorities to drive penetration, deepen competitive advantage, unlock new opportunities and scale profitably. However, macroeconomic pressures and intense competition could pose headwinds for Insulet’s operations.
In the past year, this Zacks Rank #3 (Hold) stock has lost 57.8% compared with the industry’s 27% decline. The S&P 500 composite grew 20% in the same time frame.
The developer, manufacturer and distributor of insulin delivery systems has a market capitalization of $16.21 billion. The company’s estimated long-term earnings growth rate of 22.2% is well ahead of the industry’s 12.5% rise. PODD’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 13.6%.
Let us delve deeper.
Upsides for InsuletOmnipod 5 Expanding Global Adoption: Omnipod 5 remains differentiated as a fully disposable, tubeless AID system and continues to expand its installed base across U.S. and international markets. In the second quarter of 2026, total Omnipod revenues rose 23.8% at constant currency, including U.S. growth of 20.1% and international growth of 32.9%. Global new customer starts increased sequentially and year over year, producing the company’s second-highest quarter to date.
The global customer base increased 23% year over year. More than 95% of the U.S. customer base and over 70% of the international customer base were using Omnipod 5 in the second quarter. International adoption also broadened through the Spain launch, bringing Omnipod to 26 countries and Omnipod 5 to 20. Management raised 2026 international Omnipod constant-currency growth guidance to 30% to 32%, reflecting sustained first-half momentum and continued adoption across international markets.
Progress With Strategic Actions: Insulet is extending sensor connectivity and advancing next-generation systems to deepen the Omnipod platform over time. In the second quarter of 2026, the company launched its latest U.S. Omnipod 5 algorithm update, including a 100 mg/dL target glucose option, and expanded compatibility with Abbott’s FreeStyle Libre 3 Plus. Insulet continues to target a 2027 launch for Omnipod 6 and is progressing enrollment in the EVOLVE pivotal study for its fully closed-loop Type 2 system, with a 510(k) submission still planned for 2027.
Omnipod Discover is also gaining use, with more than 12,000 people with diabetes and over 1,600 health care professionals on the platform in the second quarter. These initiatives broaden the product roadmap and may support longer-term retention and access as the company scales beyond its current user base.
Image Source: Zacks Investment Research
What Ails PODD Stock?Competitive Pressure: Insulet competes against large, established diabetes device companies and newer entrants offering pumps, smart pens and other insulin delivery approaches. As AID adoption expands globally, management expects competition to increase, which can raise commercial spending requirements and heighten payer negotiations. If competitive intensity continues to rise, Insulet may need to sustain elevated commercial spending to support customer growth, which could limit operating leverage and margin expansion.
Economic Uncertainty and Supply Exposure: Insulet remains vulnerable to geopolitical, logistics and input-cost disruptions across its global manufacturing network. The company faces risks from potential tariff expansion, supply constraints and price fluctuations among sole-source and third-party suppliers. Insulet is also expanding manufacturing capacity, including a new Costa Rica facility, which adds execution risk as production scales. The longer-term risk is that higher input costs, trade changes or supply disruptions could absorb part of the productivity and scale benefits required to sustain annual margin expansion.
PODD Stock Estimate TrendThe Zacks Consensus Estimate for Insulet’s 2026 earnings per share has moved north 0.5% to $6.51 in the past 30 days.
The same for the company’s 2026 revenues is pegged at $3.28 billion, implying a 21.1% rise from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Illumina (ILMN - Free Report) .
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% rise. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.
The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.
Zacks Premium also includes the Zacks Style Scores.
What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.
Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.
The Style Scores are broken down into four categories:
Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.
Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.
Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.
VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.
How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.
It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.
But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.
That's where the Style Scores come in.
To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.
Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.
A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.
Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.
Stock to Watch: Insulet (PODD - Free Report) Acton, MA-based Insulet Corporation manufactures and sells its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The company designed Omnipod, a small, lightweight, self-adhesive disposable tubeless device that can be worn in multiple locations, including the abdomen, hip, back of the upper arm, upper thigh or lower back.
PODD is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.
It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 22.64; value investors should take notice.
Seven analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.05 to $6.51 per share. PODD also boasts an average earnings surprise of +13.6%.
With a solid Zacks Rank and top-tier Value and VGM Style Scores, PODD should be on investors' short list.
During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products. We view Axon Enterprise as a market leading "atoms plus electrons" software provider with huge competitive moats. We sold the HeartFlow position in the quarter as we grew incrementally more concerned with the presence of competitors on the market.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) and reminds investors of the August 31, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831760201/en/
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring."
On this news, Insulet's stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction", this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery."
On this news, Insulet's stock price fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Insulet’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Insulet class action, go to www.faruqilaw.com/PODD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Insulet Securities Class Action Lawsuit:
What is the Insulet securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased Insulet securities during the Class Period. The lawsuit alleges that Insulet's manufacturing controls and procedures were defective, and that this deficiency allegedly created a foreseeable, heightened risk that one or more Insulet products would be found to violate applicable safety regulations or pose a risk of injury to patients. The complaint further alleges that, as a result, Insulet's public statements during the Class Period were materially false and misleading. The alleged truth began to emerge through two separate voluntary Medical Device Corrections disclosed by Insulet in March and May 2026, each involving manufacturing issues with specific lots of Omnipod® products, which were followed by significant declines in Insulet's stock price.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities on the NASDAQ exchange between February 21, 2025 and May 26, 2026, inclusive, may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased during the Class Period may be entitled to share in any recovery that may be obtained. Investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Additional eligibility considerations may apply, and investors are advised to consult with counsel to evaluate their specific circumstances.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative party who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy, selection of counsel, and settlement negotiations. Under the Private Securities Litigation Reform Act, any member of the proposed class may move the court for appointment as lead plaintiff, and the court will generally appoint the movant with the largest financial interest in the relief sought who otherwise satisfies applicable legal requirements. The deadline to file a motion seeking appointment as lead plaintiff in this action is August 31, 2026. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in the class or share in any recovery that may result from the litigation.
What should investors do if they purchased Insulet stock during the Class Period?
Investors who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026 are encouraged to review their brokerage and trading records to confirm whether their purchases fall within the Class Period. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications related to their Insulet holdings. Given that the lead plaintiff motion deadline is August 31, 2026, investors who wish to be considered for appointment as lead plaintiff should act promptly to avoid missing that deadline. Investors interested in learning more about the lawsuit or their potential legal rights and options may contact Faruqi & Faruqi, LLP to discuss their circumstances prior to the deadline, though retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Insulet securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260831760201/en/
New York, New York--(Newsfile Corp. - August 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312168
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Insulet to Contact Him Directly to Discuss Their Options
If you purchased or acquired securities in Insulet between February 21, 2025 and May 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) and reminds investors of the August 31, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements
ShareFaruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring."
On this news, Insulet's stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction", this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery."
On this news, Insulet's stock price fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Insulet’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Insulet class action, go to www.faruqilaw.com/PODD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Insulet Securities Class Action Lawsuit:
What is the Insulet securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased Insulet securities during the Class Period. The lawsuit alleges that Insulet's manufacturing controls and procedures were defective, and that this deficiency allegedly created a foreseeable, heightened risk that one or more Insulet products would be found to violate applicable safety regulations or pose a risk of injury to patients. The complaint further alleges that, as a result, Insulet's public statements during the Class Period were materially false and misleading. The alleged truth began to emerge through two separate voluntary Medical Device Corrections disclosed by Insulet in March and May 2026, each involving manufacturing issues with specific lots of Omnipod® products, which were followed by significant declines in Insulet's stock price.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities on the NASDAQ exchange between February 21, 2025 and May 26, 2026, inclusive, may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased during the Class Period may be entitled to share in any recovery that may be obtained. Investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Additional eligibility considerations may apply, and investors are advised to consult with counsel to evaluate their specific circumstances.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative party who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy, selection of counsel, and settlement negotiations. Under the Private Securities Litigation Reform Act, any member of the proposed class may move the court for appointment as lead plaintiff, and the court will generally appoint the movant with the largest financial interest in the relief sought who otherwise satisfies applicable legal requirements. The deadline to file a motion seeking appointment as lead plaintiff in this action is August 31, 2026. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in the class or share in any recovery that may result from the litigation.
What should investors do if they purchased Insulet stock during the Class Period?
Investors who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026 are encouraged to review their brokerage and trading records to confirm whether their purchases fall within the Class Period. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications related to their Insulet holdings. Given that the lead plaintiff motion deadline is August 31, 2026, investors who wish to be considered for appointment as lead plaintiff should act promptly to avoid missing that deadline. Investors interested in learning more about the lawsuit or their potential legal rights and options may contact Faruqi & Faruqi, LLP to discuss their circumstances prior to the deadline, though retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Insulet securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP examines the adequacy of Insulet Corporation's (NASDAQ: PODD) risk disclosures during the Class Period of February 21, 2025 through May 26, 2026. A securities class action has been filed alleging that Insulet's public filings contained materially misleading statements about manufacturing quality while defective controls at the Company's Acton, Massachusetts facility went undisclosed. Investors who lost money on PODD may find out if they qualify to recover losses from inadequate disclosures or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
Shares declined a cumulative $24.02 per share across two corrective disclosures, falling from $236.07 to $146.01, after the Company initiated Medical Device Corrections affecting millions of Omnipod insulin delivery devices. The lead plaintiff deadline is August 31, 2026.
What the Company Disclosed in SEC Filings
Insulet's FY 2024 and FY 2025 annual reports on Form 10-K contained nearly identical quality assurance language. Both filings stated that outside vendors "are audited periodically by our Quality team to confirm conformity with the specifications, policies, and procedures for our products" and that the Quality team "inspects and tests our products at various steps in the manufacturing cycle to facilitate compliance with our specifications."
Quarterly filings on Form 10-Q during the Class Period projected that gross margins would "increase compared with 2024 primarily due to improved manufacturing efficiencies."
What the Lawsuit Alleges Was Missing
The action contends that these quality assurance descriptions concealed specific, known deficiencies in Insulet's manufacturing controls at its Acton facility. The complaint charges that:
Cannula handling procedures at the Acton plant were defective, producing pods with small tears in internal tubing that could cause insulin to leak or under-deliverThe Company's quality inspection process failed to detect these defects before distribution, despite claiming multi-step testingRisk factor language in SEC filings described general manufacturing risks without disclosing that specific, identified control failures were already producing defective unitsAfter the March 2026 recall, management claimed the issue was limited to "specific lots" and that unreleased pods were "very safe to use," when the same cannula tear defect would trigger a second, far larger recall two months later Why Generic Warnings Allegedly Failed to Protect Investors
The complaint challenges the gap between Insulet's specific public assurances and its generic risk factor language. Executives made concrete representations about manufacturing quality. On earnings calls, management stated the Company had "pioneered advanced automation" and could "deliver tens of millions of complex electromechanical devices per year at medical standards." The FY 2025 earnings call featured the claim that Insulet produces pods "with high-quality medical-grade quality at consumer electronic scale."
The lawsuit maintains that generic risk disclosures about potential manufacturing problems did not cure allegedly misleading affirmative statements about product quality and manufacturing controls. The May 2026 MDC revealed that approximately 7 million pods, representing 8.5% of 2025 global production, were affected by the same type of cannula tear defect.
"Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company's operations. When a company's SEC filings describe robust quality controls while manufacturing defects are producing millions of flawed medical devices, investors are denied the information they need to make informed decisions." -- Joseph E. Levi, Esq.
LEAD PLAINTIFF DEADLINE: August 31, 2026
Speak with an attorney about Insulet's disclosure failures or call (212) 363-7500.
Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered. Attorney Advertising. Prior results do not guarantee similar outcomes.
Frequently Asked Questions About the PODD Lawsuit
Q: What specific misstatements does the PODD lawsuit allege? A: The complaint alleges Insulet made materially false or misleading statements regarding the quality and safety of its Omnipod manufacturing processes during the Class Period, while its Acton, Massachusetts facility was producing pods with defective cannula handling that caused insulin under-delivery. When two Medical Device Corrections revealed the scope of the problem, shares declined significantly.
Q: When did Insulet allegedly mislead investors? A: The class period runs from February 21, 2025 to May 26, 2026. During this time, SEC filings and executive statements allegedly presented a misleading picture of manufacturing quality. The truth emerged through corrective disclosures on March 12, 2026 and May 26, 2026.
Q: What is the PODD lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is August 31, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
Q: What if I already sold my PODD shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the class period and sold at a loss may still participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004 [email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
NEW YORK, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Insulet securities between May 21, 2025 and May 26, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/PODD.
Insulet Case Details
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:
(1) Insulet’s manufacturing controls and procedures were defective;
(2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and
(3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
What's Next for Insulet Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/PODD. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Insulet you have until August 31, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Insulet Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Insulet Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
Notice to Pension Funds, Asset Managers, and Fiduciaries Holding PODD: Institutional Portfolios Face Significant Exposure Following Two Omnipod Medical Device Corrections and Over $90 Per Share Decline from Pre-Disclosure Levels
, /PRNewswire/ -- Institutional investors holding positions in Insulet Corporation (NASDAQ: PODD) during the period from February 21, 2025 through May 26, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Click here to see if you may be eligible to recover. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.
Insulet shares declined from approximately $236 to $146.01 per share across two corrective disclosures revealing systemic manufacturing defects at the Company's Acton, Massachusetts facility. The window to apply for lead plaintiff closes on August 31, 2026.
Notice to Institutional Holders
Fiduciaries overseeing portfolios that included PODD securities during the Class Period should assess whether their funds purchased shares at prices that were allegedly artificially inflated by undisclosed manufacturing control failures. The magnitude of the stock-price declines, combined with allegations that management concealed material manufacturing deficiencies and quality-control issues affecting its Omnipod products, raises questions that fiduciaries should evaluate promptly.
Fiduciary Obligations and Recovery Options
Institutional holders should consider the following:
The stock declined approximately $24 per share across the two immediate corrective disclosures which revealed manufacturing deficiencies that contradicted management's public statements regarding manufacturing quality, product safety, and quality-control processes. The complaint alleges that Insulet failed to disclose manufacturing defects and quality-control deficiencies that ultimately resulted in two Medical Device Corrections. Institutions that purchased shares at artificially inflated prices during the Class Period may recover losses without out-of-pocket costs through the class action mechanism Lead plaintiff appointment provides direct oversight of case strategy, settlement negotiations, and counsel selection ERISA-governed plans holding PODD may have independent obligations to evaluate recovery options on behalf of plan participants Contact us to learn more about institutional recovery options or call (888) SueWallSt.
"Institutional investors play a critical role in securities class actions. Funds with significant PODD losses during the Class Period are well-positioned to serve as lead plaintiff, providing oversight that benefits the entire class while fulfilling fiduciary obligations to their own beneficiaries." — Joseph E. Levi, Esq.
To be considered for lead plaintiff, investors must file by August 31, 2026.
WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the PODD Lawsuit
Q: What is the PODD class action lawsuit about? A: A securities class action has been filed against Insulet Corporation (NASDAQ: PODD) alleging materially false and misleading statements between February 21, 2025 and May 26, 2026. Shares fell approximately 38% from their pre-disclosure price after the company disclosed two Medical Device Corrections systemic in its Omnipod insulin delivery devices, causing significant losses for shareholders.
Q: Who is eligible to join the PODD investor lawsuit? A: Investors who purchased PODD stock or securities between February 21, 2025 and May 26, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What if I already sold my PODD shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
LOS ANGELES, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Insulet Corporation (“Insulet” or “the Company”) (NASDAQ: PODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of PODD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 21, 2025 to May 26, 2026
DEADLINE: August 31, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Insulet suffered from defective controls over its manufacturing processes. The Company faced increased risks of safety violations due to these deficiencies. The Company’s manufacturing problem necessitating its March 2026 Medical Device Correction impacted a greater number of its Pod Products than it claimed. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Insulet, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Insulet securities between May 21, 2025 and May 26, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/PODD.
Insulet Case Details
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:
(1) Insulet’s manufacturing controls and procedures were defective;
(2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and
(3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
What's Next for Insulet Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/PODD. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Insulet you have until August 31, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Insulet Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Insulet Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
New York, New York--(Newsfile Corp. - August 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311700
Source: The Rosen Law Firm PA
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 26-cv-13062, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Insulet securities between February 21, 2025 and May 26, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are an investor who purchased or otherwise acquired Insulet securities during the Class Period, you have until August 31, 2026, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
[Click here for information about joining the class action]
Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States ("U.S.") and internationally.
The Company offers, inter alia, its "Omnipod 5" automated insulin delivery ("AID") system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and its "Omnipod Dash", which features a Bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager.
Insulet also formerly offered the Omnipod Insulin Management System, its predecessor to the Omnipod 5, prior to the Class Period, but had already begun to phase out the product by the start of the Class Period.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Insulet's manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring."
On this news, Insulet's stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction", this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery."
On this news, Insulet's stock price fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, both dates inclusive (the “Class Period”), have until this Monday, August 31, 2026 to seek appointment as lead plaintiff of the Insulet class action lawsuit. Captioned Hu v. Insulet Corporation, No. 26-cv-013062 (D. Mass.), the Insulet class action lawsuit charges Insulet as well as certain of Insulet’s top current and former executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Insulet class action lawsuit, please provide your information here:
You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
CASE ALLEGATIONS: Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
The Insulet class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) the manufacturing issue that precipitated Insulet’s March 2026 Medical Device Correction affected a greater number of Insulet Pod products than Insulet claimed.
On March 12, 2026, Insulet allegedly disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” On this news, the price of Insulet stock fell nearly 7%, according to the complaint.
Then, on May 26, 2026, Insulet allegedly disclosed the initation of another “voluntary Medical Device Correction,” this time “for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.” On this news, the price of Insulet stock fell more than 5%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Insulet securities during the Class Period to seek appointment as lead plaintiff in the Insulet class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Insulet class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Insulet class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Insulet class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Insulet To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Insulet between February 21, 2025 and May 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - August 28, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD) and reminds investors of the August 31, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Insulet's manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring."
On this news, Insulet's stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction", this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery."
On this news, Insulet's stock price fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Insulet's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Insulet class action, go to www.faruqilaw.com/PODD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Insulet Securities Class Action Lawsuit:
What is the Insulet securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased Insulet securities during the Class Period. The lawsuit alleges that Insulet's manufacturing controls and procedures were defective, and that this deficiency allegedly created a foreseeable, heightened risk that one or more Insulet products would be found to violate applicable safety regulations or pose a risk of injury to patients. The complaint further alleges that, as a result, Insulet's public statements during the Class Period were materially false and misleading. The alleged truth began to emerge through two separate voluntary Medical Device Corrections disclosed by Insulet in March and May 2026, each involving manufacturing issues with specific lots of Omnipod® products, which were followed by significant declines in Insulet's stock price.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities on the NASDAQ exchange between February 21, 2025 and May 26, 2026, inclusive, may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased during the Class Period may be entitled to share in any recovery that may be obtained. Investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Additional eligibility considerations may apply, and investors are advised to consult with counsel to evaluate their specific circumstances.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative party who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy, selection of counsel, and settlement negotiations. Under the Private Securities Litigation Reform Act, any member of the proposed class may move the court for appointment as lead plaintiff, and the court will generally appoint the movant with the largest financial interest in the relief sought who otherwise satisfies applicable legal requirements. The deadline to file a motion seeking appointment as lead plaintiff in this action is August 31, 2026. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in the class or share in any recovery that may result from the litigation.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Insulet securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311823
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - August 28, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Insulet securities between May 21, 2025 and May 26, 2026, both dates inclusive (the "Class Period").
If you purchased or acquired Insulet securities between February 21, 2025 and May 26, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Aug. 28, 2026 (GLOBE NEWSWIRE) --
What’s Happening?
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (“Insulet” or the “Company”) (NASDAQ:PODD) in United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Insulet securities between February 21, 2025 and May 26, 2026, both dates inclusive (the “Class Period”).Investors have until August 31, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details?
Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times. What are my Next Steps?
If you purchased or otherwise acquired Insulet shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
New York, New York--(Newsfile Corp. - August 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311702
Source: The Rosen Law Firm PA
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline.
So what: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Insulet Corporation class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
New York, New York--(Newsfile Corp. - August 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311706
Source: The Rosen Law Firm PA
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”), of the important August 31, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet’s manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827 [email protected]
www.rosenlegal.com
New York, New York--(Newsfile Corp. - August 30, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Insulet securities between May 21, 2025 and May 26, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/PODD.
Insulet Case Details
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:
Insulet's manufacturing controls and procedures were defective; the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and as a result, Defendants' public statements were materially false and misleading at all relevant times.What's Next for Insulet Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/PODD. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Insulet you have until August 31, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Insulet Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Insulet Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising.
Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311153
Source: Bronstein, Gewirtz & Grossman, LLC
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
New York, New York--(Newsfile Corp. - August 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311707
Source: The Rosen Law Firm PA
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Insulet To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Insulet between February 21, 2025 and May 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - August 30, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insulet Corporation ("Insulet" or the "Company") (NASDAQ: PODD) and reminds investors of the August 31, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) Insulet's manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.
The truth began to emerge on March 12, 2026, when Insulet disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring."
On this news, Insulet's stock price fell $16.23 per share, or 6.88%, to close at $219.84 per share on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the "initat[ion]" of another "voluntary Medical Device Correction", this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery."
On this news, Insulet's stock price fell $7.79 per share, or 5.07%, to close at $146.01 per share on May 27, 2026.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Insulet's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Insulet class action, go to www.faruqilaw.com/PODD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Frequently Asked Questions (FAQ) for Investors Regarding the Insulet Securities Class Action Lawsuit:
What is the Insulet securities fraud lawsuit about?
Faruqi & Faruqi, LLP has filed a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD) on behalf of investors who purchased Insulet securities during the Class Period. The lawsuit alleges that Insulet's manufacturing controls and procedures were defective, and that this deficiency allegedly created a foreseeable, heightened risk that one or more Insulet products would be found to violate applicable safety regulations or pose a risk of injury to patients. The complaint further alleges that, as a result, Insulet's public statements during the Class Period were materially false and misleading. The alleged truth began to emerge through two separate voluntary Medical Device Corrections disclosed by Insulet in March and May 2026, each involving manufacturing issues with specific lots of Omnipod® products, which were followed by significant declines in Insulet's stock price.
Who may be eligible to participate in the lawsuit?
Investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities on the NASDAQ exchange between February 21, 2025 and May 26, 2026, inclusive, may be eligible to participate in this lawsuit. Eligibility to participate is not limited to those who seek appointment as lead plaintiff; any investor who purchased during the Class Period may be entitled to share in any recovery that may be obtained. Investors are encouraged to review their trading records to determine whether their purchases fall within the defined Class Period. Additional eligibility considerations may apply, and investors are advised to consult with counsel to evaluate their specific circumstances.
What is a lead plaintiff, and how can I seek appointment?
A lead plaintiff is a court-appointed representative party who acts on behalf of all class members in directing the litigation, including making key decisions regarding litigation strategy, selection of counsel, and settlement negotiations. Under the Private Securities Litigation Reform Act, any member of the proposed class may move the court for appointment as lead plaintiff, and the court will generally appoint the movant with the largest financial interest in the relief sought who otherwise satisfies applicable legal requirements. The deadline to file a motion seeking appointment as lead plaintiff in this action is August 31, 2026. Importantly, investors are not required to seek appointment as lead plaintiff in order to participate in the class or share in any recovery that may result from the litigation.
What should investors do if they purchased Insulet stock during the Class Period?
Investors who purchased Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026 are encouraged to review their brokerage and trading records to confirm whether their purchases fall within the Class Period. Investors should take steps to preserve all relevant documentation, including trade confirmations, account statements, and any communications related to their Insulet holdings. Given that the lead plaintiff motion deadline is August 31, 2026, investors who wish to be considered for appointment as lead plaintiff should act promptly to avoid missing that deadline. Investors interested in learning more about the lawsuit or their potential legal rights and options may contact Faruqi & Faruqi, LLP to discuss their circumstances prior to the deadline, though retaining counsel or seeking lead plaintiff status is not required to participate in any potential class recovery.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Insulet securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311866
Source: Faruqi & Faruqi LLP
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Insulet Corporation ("Insulet" or "the Company") (NASDAQ: PODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of PODD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 21, 2025 to May 26, 2026
DEADLINE: August 31, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Insulet failed to maintain appropriate controls over its manufacturing processes. The Company's manufacturing problems created safety risks for its customers. Based on these facts, Insulet's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. As one of the founding partners of Schall Brown & Schwartz LLP (schallfirm.com), David Schwartz specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
, /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Insulet Corporation ("Insulet" or "the Company") (NASDAQ: PODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
If you purchased Insulet Corporation securities you may be entitled to compensation without payment of any out-of-pocket fees or costs. Shareholders who purchased shares of PODD during the class period listed are encouraged to contact SBS to find out if they are eligible to recover their losses or lead this lawsuit. Appointment as lead plaintiff is not required to partake in any recovery. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
CLASS PERIOD: February 21, 2025 to May 26, 2026
DEADLINE: August 31, 2026
If you are a shareholder who suffered a loss, click here to participate.
Details of the Case: According to the Complaint, the Company made false and misleading statements to the market. Insulet suffered from defective controls over its manufacturing processes. The Company faced increased risks of safety violations due to these deficiencies. The Company's manufacturing problem necessitating its March 2026 Medical Device Cirrection impacted a greater number of its Pod Products than it claimed. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Insulet, investors suffered damages.
We encourage investors to contact Brian Schall and David Schwartz of Schall Brown & Schwartz, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
Why SBS: Schall Brown & Schwartz represents investors around the world, specializing in securities class action lawsuits and shareholder rights litigation. SBS brings together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz. SBS attorneys and their co-counsel are responsible for recovering over a billion dollars for violations of securities laws and corporate misfeasance.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
Insulet Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - PODD PR Newswire
LOS ANGELES, Aug. 31, 2026
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Insulet Corporation ("Insulet" or "the Company") (NASDAQ: PODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of PODD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 21, 2025 to May 26, 2026
DEADLINE: August 31, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Insulet failed to maintain appropriate controls over its manufacturing processes. The Company's manufacturing problems created safety risks for its customers. Based on these facts, Insulet's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. As one of the founding partners of Schall Brown & Schwartz LLP (schallfirm.com), David Schwartz specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
View original content:https://www.prnewswire.com/news-releases/insulet-corporation-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--podd-302864538.html
, /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Insulet Corporation ("Insulet" or "the Company") (NASDAQ: PODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
If you purchased Insulet Corporation securities you may be entitled to compensation without payment of any out-of-pocket fees or costs. Shareholders who purchased shares of PODD during the class period listed are encouraged to contact SBS to find out if they are eligible to recover their losses or lead this lawsuit. Appointment as lead plaintiff is not required to partake in any recovery. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
CLASS PERIOD: February 21, 2025 to May 26, 2026
DEADLINE: August 31, 2026
If you are a shareholder who suffered a loss, click here to participate.
Details of the Case: According to the Complaint, the Company made false and misleading statements to the market. Insulet suffered from defective controls over its manufacturing processes. The Company faced increased risks of safety violations due to these deficiencies. The Company's manufacturing problem necessitating its March 2026 Medical Device Cirrection impacted a greater number of its Pod Products than it claimed. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Insulet, investors suffered damages.
We encourage investors to contact Brian Schall and David Schwartz of Schall Brown & Schwartz, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
Why SBS: Schall Brown & Schwartz represents investors around the world, specializing in securities class action lawsuits and shareholder rights litigation. SBS brings together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz. SBS attorneys and their co-counsel are responsible for recovering over a billion dollars for violations of securities laws and corporate misfeasance.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
View original content:https://www.prnewswire.com/news-releases/insulet-corporation-investor-alert-contact-sbs-by-august-31-2026-for-opportunity-to-lead-securities-fraud-lawsuit-302864539.html
San Diego, California--(Newsfile Corp. - August 24, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, both dates inclusive (the "Class Period"), have until August 31, 2026 to seek appointment as lead plaintiff of the Insulet class action lawsuit. Captioned Hu v. Insulet Corporation, No. 26-cv-013062 (D. Mass.), the Insulet class action lawsuit charges Insulet and certain of Insulet's top current and former executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Insulet class action lawsuit, please provide your information here:
You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
CASE ALLEGATIONS: Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes.
The Insulet class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Insulet's manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) the manufacturing issue that precipitated Insulet's March 2026 Medical Device Correction affected a greater number of Insulet Pod products than Insulet claimed.
On March 12, 2026, Insulet allegedly disclosed that it had "initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring." On this news, the price of Insulet stock fell nearly 7%, according to the complaint.
Then, on May 26, 2026, Insulet allegedly disclosed the initation of another "voluntary Medical Device Correction," this time "for specific lots of Omnipod® 5, Omnipod Dash®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery." On this news, the price of Insulet stock fell more than 5%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Insulet securities during the Class Period to seek appointment as lead plaintiff in the Insulet class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Insulet class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Insulet class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Insulet class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors — $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever — $7.2 billion — in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
, /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Insulet Corporation.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INSULET CORPORATION (PODD), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 31, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Is The Lawsuit About?
The complaint filed in this class action alleges that between February 21, 2025 and May 26, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com
If you purchased or acquired Insulet securities between February 21, 2025 and May 26, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (“Insulet” or the “Company”) (NASDAQ:PODD) in United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Insulet securities between February 21, 2025 and May 26, 2026, both dates inclusive (the “Class Period”).Investors have until August 31, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:
Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Insulet’s manufacturing controls and procedures were defective; (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (iii) as a result, Defendants’ public statements were materially false and misleading at all relevant times. Next Steps:
If you purchased or otherwise acquired Insulet shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”). Insulet develops, manufactures, and sells insulin delivery systems.For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Firm is Investigating the Alle.
Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”). Insulet develops, manufactures, and sells insulin delivery systems.
For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.
The Allegations: Rosen Law Firm is Investigating the Allegations that Insulet Corporation (NASDAQ: PODD) Misled Investors Regarding its Business Operations.
According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet’s manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
What Now: You may be eligible to participate in the class action against Insulet. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 31, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $2 billion for shareholders.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260824635481/en/
NEW YORK, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ: PODD) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Insulet securities between May 21, 2025 and May 26, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/PODD.
Insulet Case Details
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:
(1) Insulet’s manufacturing controls and procedures were defective;
(2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and
(3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
What's Next for Insulet Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/PODD. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Insulet you have until August 31, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
No Cost to Insulet Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Insulet Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
New York, New York--(Newsfile Corp. - August 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Insulet Corporation (NASDAQ: PODD) between February 21, 2025 and May 26, 2026, inclusive (the "Class Period"), of the important August 31, 2026 lead plaintiff deadline.
SO WHAT: If you purchased Insulet securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 31, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Insulet's manufacturing controls and procedures were defective; (2) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Insulet class action, go to https://rosenlegal.com/cases/insulet-corporation/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/311115
Source: The Rosen Law Firm PA
Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
